275 related articles for article (PubMed ID: 28516725)
41. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease.
Kochhar GS; Desai A; Caldera DO F; El Hachem S; Aoun E; Sandhu D; Mohan BP; Dulai PS; Farraye FA
Vaccine; 2021 Jul; 39(30):4199-4202. PubMed ID: 34140170
[TBL] [Abstract][Full Text] [Related]
43. Zoster vaccine: current status and future prospects.
Oxman MN
Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454
[TBL] [Abstract][Full Text] [Related]
44. Herpes Zoster Vaccination: Controversies and Common Clinical Questions.
Van Epps P; Schmader KE; Canaday DH
Gerontology; 2016; 62(2):150-4. PubMed ID: 26184711
[TBL] [Abstract][Full Text] [Related]
45. [Prevention of herpes zoster by vaccination].
Kofoed K; Rønholt F; Gerstoft J; Sand C
Ugeskr Laeger; 2011 Jan; 173(2):110-4. PubMed ID: 21219841
[TBL] [Abstract][Full Text] [Related]
46. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients.
Caldera F; Saha S; Wald A; Garmoe CA; McCrone S; Megna B; Ley D; Reichelderfer M; Hayney MS
Dig Dis Sci; 2018 Jun; 63(6):1532-1540. PubMed ID: 29594970
[TBL] [Abstract][Full Text] [Related]
47. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases.
Beaugerie L; Rahier JF; Kirchgesner J
Clin Gastroenterol Hepatol; 2020 May; 18(6):1324-1335.e2. PubMed ID: 32059920
[TBL] [Abstract][Full Text] [Related]
48. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
[TBL] [Abstract][Full Text] [Related]
49. Improving herpes zoster vaccine rates: The impact of a targeted educational program.
OʼDonnell M; Shurpin K; Janotha B
J Am Assoc Nurse Pract; 2018 Aug; 30(8):435-440. PubMed ID: 29905591
[TBL] [Abstract][Full Text] [Related]
50. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.
Wung PK; Holbrook JT; Hoffman GS; Tibbs AK; Specks U; Min YI; Merkel PA; Spiera R; Davis JC; St Clair EW; McCune J; Ytterberg SR; Allen NB; Stone JH;
Am J Med; 2005 Dec; 118(12):1416. PubMed ID: 16378799
[TBL] [Abstract][Full Text] [Related]
51. The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents.
Khan N; Trivedi C; Shah Y; Patel D; Lewis J; Yang YX
Inflamm Bowel Dis; 2018 May; 24(6):1274-1279. PubMed ID: 29522099
[TBL] [Abstract][Full Text] [Related]
52. Herpes zoster vaccine. Poorly effective in those who need it most.
Prescrire Int; 2012 Dec; 21(133):291. PubMed ID: 23373094
[TBL] [Abstract][Full Text] [Related]
53. [Vaccines against varicella-zoster virus (VZV)].
Salleras L; Salleras M; Soldevila N; Prat A; Garrido P; Domínguez Á
Enferm Infecc Microbiol Clin; 2015; 33(6):411-23. PubMed ID: 26096575
[TBL] [Abstract][Full Text] [Related]
54. Varicella vaccination in the immunocompromised.
Malaiya R; Patel S; Snowden N; Leventis P
Rheumatology (Oxford); 2015 Apr; 54(4):567-9. PubMed ID: 24758889
[No Abstract] [Full Text] [Related]
55. [Pain in herpes zoster: Prevention and treatment].
Calvo-Mosquera G; González-Cal A; Calvo-Rodríguez D; Primucci CY; Plamenov-Dipchikov P
Semergen; 2017; 43(4):318-327. PubMed ID: 27053513
[TBL] [Abstract][Full Text] [Related]
56. Live attenuated herpes zoster vaccine for HIV-infected adults.
Shafran SD
HIV Med; 2016 Apr; 17(4):305-10. PubMed ID: 26315285
[TBL] [Abstract][Full Text] [Related]
57. Varicella zoster virus redux.
Gelb LD
Herpes; 2009 Jan; 15(3):62-3. PubMed ID: 19306605
[TBL] [Abstract][Full Text] [Related]
58. Quantification of risk factors for herpes zoster: population based case-control study.
Forbes HJ; Bhaskaran K; Thomas SL; Smeeth L; Clayton T; Langan SM
BMJ; 2014 May; 348():g2911. PubMed ID: 25134101
[TBL] [Abstract][Full Text] [Related]
59. Relevant Infections in Inflammatory Bowel Disease, and Their Relationship With Immunosuppressive Therapy and Their Effects on Disease Mortality.
Zabana Y; Rodríguez L; Lobatón T; Gordillo J; Montserrat A; Mena R; Beltrán B; Dotti M; Benitez O; Guardiola J; Domènech E; Garcia-Planella E; Calvet X; Piqueras M; Aceituno M; Fernández-Bañares F; Esteve M
J Crohns Colitis; 2019 Jul; 13(7):828-837. PubMed ID: 30668662
[TBL] [Abstract][Full Text] [Related]
60. Prevaccination epidemiology of herpes zoster in Denmark: Quantification of occurrence and risk factors.
Schmidt SAJ; Vestergaard M; Baggesen LM; Pedersen L; Schønheyder HC; Sørensen HT
Vaccine; 2017 Oct; 35(42):5589-5596. PubMed ID: 28874322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
